Find an expert
Our panel of editors are available for interview
Dr Brandy Shillace
Editor-in-Chief of Medical Humanities
Brandy Schillace, PhD, is Senior Research Associate and Public Engagement and Programs Leader for the Dittrick Museum of Medical History. Dr Schillace writes about intersections of medicine, history, and literature. For ten years, she managed the medical anthropology journal, Culture, Medicine and Psychiatry, and edited its first medical humanities special issue. Brandy’s recent books include Death’s Summer Coat (2016), Clockwork Futures (2017) and Mr Humble and Dr Butcher: A Monkey’s Head, the Pope’s Neuroscientist, and the Quest to Transplant the Soul (2021).
Dr James Mountford
Editor-in-Chief of BMJ Leader
Dr James Mountford is Director of Quality at Royal Free London NHS Foundation Trust. He worked initially as an NHS doctor, then in consulting. From 2005-2007, he was a Commonwealth Fund Health Foundation Harkness Fellow based in Massachusetts General Hospital, and at the Institute for Healthcare Improvement (IHI), both in Boston, USA. Before moving to the Royal Free, he was Director of Quality at UCL Partners, an academic health sciences partnership serving a population of 3 million in and around London. He sits on the board of AQuA, the improvement partnership based in north-west England. In March 2020 he was seconded to work as the Chief of Quality and Learning at the NHS Nightingale Hospital London, opened in response to the COVID-19 pandemic.
Professor Ronald F. van Vollenhoven
Editor-in-Chief of Lupus Science & Medicine
Professor Ronald F. van Vollenhoven is a distinguished rheumatologist and immunologist, known for his significant contributions in the field. He currently holds the position of Chair of the Department of Rheumatology and Clinical Immunology at Amsterdam UMC and directs the Amsterdam Rheumatology Centre. With a background in immunology and extensive training in Internal Medicine and Rheumatology, he has dedicated his career to the development and evaluation of biological and immunomodulatory treatments for rheumatic diseases. Dr. Van Vollenhoven has played a pivotal role in establishing crucial registries, including the Stockholm registry for biological therapies (STURE database), and has been a principal investigator in numerous clinical trials.
Professor Anna Maria Geretti
Editor-in-Chief of Sexually Transmitted Infections
Anna Maria Geretti, MD, PhD, FRCPath, is Professor of Virology & Infectious Diseases at the Institute of Infection & Global Health of the University of Liverpool, and Honorary Consultant at the Royal Liverpool University Hospital. She trained in Italy, the Netherlands and the UK and has a special interest in HIV, hepatitis B and hepatitis C infection. She has published over 100 peer-reviewed articles, editorials, reviews and book chapters, runs capacity building programmes for resource-limited countries and enthusiastically shares her expertise to train doctors and scientists.
Professor Hans Kromhout
Editor-in-Chief of Occupational & Environmental Medicine
Professor Hans Kromhout is an occupational hygiene and epidemiology specialist, based at the Institute for Risk Assessment Sciences at Utrecht University in the Netherlands. Professor Kromhout’s work has covered the health effects of chemical and physical (EMF) agents in the workplace and general environment. He has been the (co-)PI of large international studies in among others the asphalt industry, rubber manufacturing industry, industrial minerals industry, health sector and agriculture and community based studies on cancer, respiratory diseases, neurodegenerative diseases and reproductive health effects.
Professor Ganesan Karthikeyan
Editor-in-Chief Open Heart
Professor Karthikeyan is a clinical, interventional cardiologist and a Senior International Fellow of the Population Health Research Institute at McMaster University in Canada, as well as Professor of Cardiology at AIIMS. His research is mainly focused on cardiovascular diseases affecting low and middle income countries, including valvular heart disease, particularly rheumatic heart disease (RHD), mechanical valve thrombosis, anticoagulation, and indigenous drug-eluting stents.
